RMC-9805

PreclinicalSmall molecule

RMC-9805 is one of 27 small molecule programs targeting Non-small Cell Lung Cancer (NSCLC). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung Cancer (NSCLC)Recruiting

Non-Small Cell Lung Cancer (NSCLC)Preclinical

Recruiting

Competition

Competitive Landscape

31 competitors in Non-Small Cell Lung Cancer (NSCLC)

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

3 2

Imfinzi

AstraZeneca

Phase 3

3 3

DATROWAY

Daiichi Sankyo

Phase 3

1 4

Alimta

GGynecologic Oncology Group

Phase 3

3 5

Paraplatin

AAvyxa

Phase 3

3 6

Taxotere

AAvyxa

Phase 3

2 7

Tylenol

KKenvue Brands

Phase 3

1 8

Decadron

AAspen Global Incorporated

Phase 3

1 9

Pumitamig

Bristol-Myers Squibb

Phase 3

3 10

Sacituzumab Tirumotecan

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Solid Tumors

NCT06040541

Q3 2027

Phase 1/2Recruiting

Gastrointestinal

NCT06445062

Q4 2027

Phase 1/2Recruiting

Efficacy

NCT06922591

Q4 2028

PreclinicalRecruiting

Non-Small Cell Lung Cancer (NSCLC)

NCT06162221

Clinical

Trials by Indication[1]

Gastrointestinal1 trial

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Recruiting· Revolution Medicines logo

Revolution Medicines·Phase 1/2·NCT06445062·1,130 enrolled

Efficacy1 trial

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Recruiting·TTango Therapeutics, Inc.·Phase 1/2·NCT06922591·183 enrolled

Solid Tumors1 trial

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Recruiting· Revolution Medicines logo

Revolution Medicines·Phase 1·NCT06040541·604 enrolled

Non-small Cell Lung Cancer (NSCLC)1 trial

A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)

Recruiting· Revolution Medicines logo

Revolution Medicines·Preclinical·NCT06162221·616 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for RMC-9805. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RMC-9805 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RMC-9805. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Revolution Medicines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Revolution Medicines

RMC-9805

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q4 2027

Q4 2028

Trials by Indication[1]

Gastrointestinal1 trial

Efficacy1 trial

Solid Tumors1 trial

Non-small Cell Lung Cancer (NSCLC)1 trial

References

Drug Info

Quick Facts

Related News